NHS England South West - Diabetic Eye Screening Programmes for Cornwall, Devon, Somerset, Gloucestershire and Bristol, North Somerset, South Gloucestershire (BNSSG) (Великобритания (Англия, Шотландия, Уэльс) - Тендер #43053821)

Print or Save this Notice Download PDF Download HTML Download XML

Social and other specific services – public contracts

Contract notice

Section I: Contracting authority

I.1) Name and addresses

NHS England

Three-Six-Zero - 360, Marlborough Street

Bristol

BS1 3NX

UK

Contact person: Hannah Morley

E-mail: scwcsu.procurement@nhs.net

NUTS: UKK11

Internet address(es)

Main address: https://www.england.nhs.uk/south/

Address of the buyer profile: https://health-family.force.com/s/Welcome

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge at:

https://health-family.force.com/s/Welcome

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be sent electronically to:

https://health-family.force.com/s/Welcome

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS England South West - Diabetic Eye Screening Programmes for Cornwall, Devon, Somerset, Gloucestershire and Bristol, North Somerset, South Gloucestershire (BNSSG)

Reference number: C185632

II.1.2) Main CPV code

85000000

II.1.3) Type of contract

Services

II.1.4) Short description

NHSE South West (The Commissioner) seeks to re-commission five Diabetic Eye Screening Programmes (DESP) to deliver screening to the eligible populations of Cornwall and Isles of Scilly (Lot 1), Devon (Lot 2), Somerset (Lot 3), Gloucestershire (Lot 4), and Bristol, North Somerset and South Gloucestershire (BNSSG) (Lot 5).

The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.

The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.

This will be achieved by delivering an evidence-based service that:

•Identifies the eligible population and ensures effective delivery with maximum coverage

•Is safe, effective, high quality, externally and independently monitored, and quality assured

•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes

•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes

•Has audit embedded in the service

•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient

There are 3 key elements of service delivery, namely:

•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance

•Digital surveillance where individuals need more frequent screening

•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).

Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.

The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.

The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contracts are due to commence on 1st April 2024.

The 9 year estimated contract values, based on predicted activity levels, are:

Lot 1 = £9,588,607

Lot 2 = £24,522,731

Lot 3 = £13,581,836

Lot 4 = £11,231,506

Lot 5 = £15,468,533

The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.

The Commissioner"s ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).

National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.

This procurement is being carried out by NHS South, Central and West Commissioning Support Unit (SCW) on behalf of the Commissioners.

Interested providers will be able to view the opportunity and access the tender documentation via the "Live Opportunities" list on the e-procurement system, Atamis, available on the following link: https://health-family.force.com/s/Welcome

II.1.5) Estimated total value

Value excluding VAT: 74 393 213.00 GBP

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

II.2) Description

Lot No: 1

II.2.1) Title

Diabetic Eye Screening Programme for Cornwall and Isles of Scilly

II.2.2) Additional CPV code(s)

85000000

II.2.3) Place of performance

NUTS code:

UKK3

II.2.4) Description of the procurement

NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Cornwall and Isles of Scilly.

The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.

The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.

This will be achieved by delivering an evidence-based service that:

•Identifies the eligible population and ensures effective delivery with maximum coverage

•Is safe, effective, high quality, externally and independently monitored, and quality assured

•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes

•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes

•Has audit embedded in the service

•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient

There are 3 key elements of service delivery, namely:

•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance

•Digital surveillance where individuals need more frequent screening

•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).

Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.

The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.

The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.

The 9 year estimated contract value, based on predicted activity levels, is £9,588,607.

The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.

The Commissioner"s ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).

National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.

II.2.6) Estimated value

Value excluding VAT: 9 588 607.00 GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 108

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).

Lot No: 2

II.2.1) Title

Diabetic Eye Screening Programme for Devon

II.2.2) Additional CPV code(s)

85000000

II.2.3) Place of performance

NUTS code:

UKK4

II.2.4) Description of the procurement

NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Devon.

The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.

The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.

This will be achieved by delivering an evidence-based service that:

•Identifies the eligible population and ensures effective delivery with maximum coverage

•Is safe, effective, high quality, externally and independently monitored, and quality assured

•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes

•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes

•Has audit embedded in the service

•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient

There are 3 key elements of service delivery, namely:

•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance

•Digital surveillance where individuals need more frequent screening

•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).

Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.

The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.

The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.

The 9 year estimated contract value, based on predicted activity levels, is £24,522,731.

The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.

The Commissioner"s ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).

National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.

II.2.6) Estimated value

Value excluding VAT: 24 522 731.00 GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 108

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).

Lot No: 3

II.2.1) Title

Diabetic Eye Screening Programme for Somerset

II.2.2) Additional CPV code(s)

85000000

II.2.3) Place of performance

NUTS code:

UKK23

II.2.4) Description of the procurement

NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Somerset.

The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.

The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.

This will be achieved by delivering an evidence-based service that:

•Identifies the eligible population and ensures effective delivery with maximum coverage

•Is safe, effective, high quality, externally and independently monitored, and quality assured

•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes

•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes

•Has audit embedded in the service

•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient

There are 3 key elements of service delivery, namely:

•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance

•Digital surveillance where individuals need more frequent screening

•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).

Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.

The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.

The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.

The 9 year estimated contract value, based on predicted activity levels, is £13,581,836.

The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.

The Commissioner"s ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).

National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.

II.2.6) Estimated value

Value excluding VAT: 13 581 836.00 GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 108

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).

Lot No: 4

II.2.1) Title

Diabetic Eye Screening Programme for Gloucestershire

II.2.2) Additional CPV code(s)

85000000

II.2.3) Place of performance

NUTS code:

UKK13

II.2.4) Description of the procurement

NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Gloucestershire.

The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.

The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.

This will be achieved by delivering an evidence-based service that:

•Identifies the eligible population and ensures effective delivery with maximum coverage

•Is safe, effective, high quality, externally and independently monitored, and quality assured

•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes

•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes

•Has audit embedded in the service

•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient

There are 3 key elements of service delivery, namely:

•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance

•Digital surveillance where individuals need more frequent screening

•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).

Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.

The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.

The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.

The 9 year estimated contract value, based on predicted activity levels, is £11,231,506.

The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.

The Commissioner"s ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).

National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.

II.2.6) Estimated value

Value excluding VAT: 11 231 506.00 GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 108

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).

Lot No: 5

II.2.1) Title

Diabetic Eye Screening Programme for Bristol, North Somerset and South Gloucestershire (BNSSG)

II.2.2) Additional CPV code(s)

85000000

II.2.3) Place of performance

NUTS code:

UKK1

II.2.4) Description of the procurement

NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Bristol, North Somerset and South Gloucestershire (BNSSG).

The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.

The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.

This will be achieved by delivering an evidence-based service that:

•Identifies the eligible population and ensures effective delivery with maximum coverage

•Is safe, effective, high quality, externally and independently monitored, and quality assured

•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes

•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes

•Has audit embedded in the service

•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient

There are 3 key elements of service delivery, namely:

•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance

•Digital surveillance where individuals need more frequent screening

•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).

Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.

The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.

The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.

The 9 year estimated contract value, based on predicted activity levels, is £15,468,533.

The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.

The Commissioner"s ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).

National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.

II.2.6) Estimated value

Value excluding VAT: 15 468 533.00 GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 108

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S:

2023/S 000-009618

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 08/08/2023

Local time: 12:00

IV.2.4) Languages in which tenders or requests to participate may be submitted

EN

Section VI: Complementary information

VI.3) Additional information

Interested providers will be able to view the opportunity and access the tender documentation via the "Live Opportunities" list on the "Health Family" e-procurement system, Atamis. Click on "View our Live Opportunities" from the home page, available on the following link: https://health-family.force.com/s/Welcome.

Once you have found the opportunity (via the search function, using the title or reference number), to gain full access to the tender documentation (including questionnaires), you will need to click on "Register interest" - this will take you to the log-in page.

If you are not already registered on the system, you will need to do so before gaining full access to the documentation and be able to submit a bid.

The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).

The tendering process will be conducted in accordance with the requirements and flexibilities provided by Articles 74 to 76 of the Directive, and Regulations 74 to 76 of the Regulations. The Authority will run a transparent tender process, treating all Bidders equally. For the avoidance of doubt, the Authority will not be bound by the Regulations or any other regulations or legislation except for the specific parts or circumstances that apply to the procurement of these Services.

Neither the inclusion of a Bidder selection stage, nor the use of any language or terms found in the Directive or Regulations, nor the description of the procedure voluntarily adopted by the Authority ("Open", "Restricted", "Competitive Procedure with Negotiation", "Competitive Dialogue" or any other description), nor any other indication, shall be taken to mean that the Authority intends to hold itself bound by the Directive or Regulations, save by the provisions applicable to services coming within the scope of Annex XIV of the Directive / Schedule 3 of the Regulations.

The Contracting Authority intends to voluntarily observe the award decision notices provisions and 10 day standstill period described in Regulation 87 of the Regulations.

VI.4) Procedures for review

VI.4.1) Review body

High Court in London

London

UK

VI.5) Date of dispatch of this notice

21/06/2023

Information added to the notice since publication.

Additional information added to the notice since it"s publication.

Commodity Categories

Commodity Categories

Delivery Locations

Delivery Locations

Alert Region Restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

Alert Region Restrictions

Источник закупки

Перейти

Импорт - Экспорт по стране Великобритания (Англия, Шотландия, Уэльс)